- Areas of Interest
- Techniques
- Systems
- Products & Services
- Informatics
- Science & Education
- Company
- Support
Illumina next-generation sequencing (NGS) and microarray technologies represent the gold standard in quality worldwide—and account for ~90% of the world’s sequencing data.* Innovative, intuitive, and completely integrated, our sample-to-data solutions empower your lab to keep ahead of the curve in the rapidly evolving genomics revolution. So you’ll be better able to perform the world-class research you strive for—with the goal of uncovering new insights into the biology of cancer that can lead to meaningful advances in personalized medicine.
Our comprehensive product offerings support multiple cancer research applications, including studies of DNA, RNA, epigenetics, and more. Our range of sequencers can be scaled to meet your needs—from powerful, yet personal, benchtop models to versatile, high-throughput systems. With intuitive data analysis and management capabilities and unsurpassed customer support, we can deliver the answers you seek—quickly, accurately, and cost-effectively.
Explore genomics-based approaches to investigating cancer using NGS and microarrays.
NGS methods enable cancer researchers to perform whole-genome studies, targeted gene profiling, tumor-normal comparisons, and more. NGS also offers the sensitivity to detect rare somatic variants, tumor subclones, and circulating DNA fragments.
Immuno-oncology is an emerging field that has taken great strides in the fight against cancer, bolstered by a refined understanding of how tumors evade the natural immune response. Research into the mechanisms tumors use to inhibit the immune response have led to promising therapeutic targets.
Changes in gene activation or gene silencing can impact the rate of cancer progression. Studying the epigenetic changes that influence gene expression can provide insight into important tumorigenic pathways.
Genomic instability and chromosomal abnormalities are common features of cancer. Understanding these structural aberrations can inform studies of cancer etiology.
Illumina offers various NGS and microarray products and services to support cancer genomics research.
Learn more about Illumina technology and how it is being used in cancer research. Access publications, videos, webinars, and other educational resources.
Researchers perform RNA-Seq, ChIP-Seq, and exome sequencing in their search for gene expression profiles associated with cancer.
Read Interview
RNA-Seq and HLA typing are increasing the power and efficiency of a target discovery platform.
Read Interview
Researchers use targeted RNA sequencing to understand the role of fusion genes in pediatric leukemia.
Read InterviewHigh-quality, high-coverage sequencing offers a comprehensive view of the genome to detect variants accurately, characterize isoforms, and more. With increased throughput and reduced price per sample, the NovaSeq 6000 System is ideal for data-intensive applications.
View System
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.
Learn MoreFlexible desktop sequencing system that supports various applications, from targeted panels to whole-genome sequencing.
Learn MoreThe Illumina genomics computing environment for NGS data analysis and management, so labs can analyze, archive, and share data easily.
Learn More
Learn the numerous ways that genomic technologies can be applied to tumor biology.
An overview of recent cancer genomics research publications featuring Illumina technology.
Munich Leukemia Laboratory is using NGS to gain a better understanding of leukemia and lymphoma subtypes and discover new therapeutic pathways.
A Garvan Institute sarcoma study identifies rare cancer-associated variants in the germline.
All the information you need, from BeadChips to library preparation to sequencer selection and analysis. Select the best tools for your lab.
A researcher from Massachusetts General Hospital compares sequencing results from FFPE and fresh-frozen tumor samples.
*Data on file based on a 2013 study.